Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Study Questions:

What is the efficacy of conventional treatment aimed at maintaining the recommended hematocrit target of <45%, as compared with a level of 45-50%, for the prevention of thrombotic events in patients with polycythemia vera?